Table 1.
Characteristics of the patients.
| CT-P6 (n = 20) | RTZ (n = 24) | P∗ | |
|---|---|---|---|
| Age (years) | |||
| Mean | 48 (4.9) | 60 (11.2) | 0.001 |
| Weight (kg) | |||
| Mean | 68.4 (11.0) | 68.2 (10.3) | 0.951 |
| Clinical stage | 0.298 | ||
| I | 0 (0%) | 1 (4%) | |
| IIa | 13 (65%) | 9 (38%) | |
| IIb | 5 (25%) | 10 (42%) | |
| IIIa | 1 (5%) | 3 (12%) | |
| IIIb | 1 (5%) | 0 (0%) | |
| IIIc | 0 (0%) | 1 (4%) | |
| IV | 0 (0%) | 0 (0%) | |
| Nodal status | 0.263 | ||
| Positive | 10 (50%) | 16 (67%) | |
| Negative | 10 (50%) | 8 (33%) | |
| Hormone status | 0.223 | ||
| Estrogen receptor | |||
| Positive | 14 (70%) | 13 (54%) | |
| Negative | 6 (30%) | 11 (46%) | |
| Progesterone receptor | 0.146 | ||
| Positive | 12 (60%) | 19 (79%) | |
| Negative | 8 (40%) | 5 (21%) | |
| Grade | 0.363 | ||
| G1 | 1 (5%) | 0 (0%) | |
| G2 | 5 (25%) | 8 (42%) | |
| G3 | 14 (70%) | 11 (58%) | |
| Ki67 (%) | 0.974 | ||
| Median | 40 (18–70) | 40 (10–70) | |
| LVEF (%) | |||
| Median | 66 (57–77) | 65 (56–78) | 0.270 |
| Neoadjuvant chemotherapy | 0.873 | ||
| AC-THP | 19 (95%) | 23 (96%) | |
| TCHP | 1 (5%) | 1 (4%) | |
Data are mean (SD), median (range), or n (%). LVEF = left ventricular ejection fraction. AC-THP = doxorubicin + cyclophosphamide followed by paclitaxel or nab-paclitaxel + trastuzumab + pertuzumab. TCHP = docetaxel + carboplatin + trastuzumab + pertuzumab. ∗p-value from Chi-Square test or Student's t-test; p-value under 0.05 is considered as statistical significant.